PDS Biotechnology Accepted for Oral Presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting

NEXT STORY
Translate Bio Announces Third Quarter 2019 Financial Results and Reviews Recent Highlights
PREV STORY
Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Strongbridge Biopharma plc Announces Publication of Diabetes Subgroup Analysis from Phase 3 SONICS Study of RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in Frontiers in Endocrinology

author_avatar
NASDAQ Market News

Orchard Therapeutics Highlights 2020 Strategic Priorities

author_avatar
NASDAQ Market News

Coherus Acquires Commercial Rights for Leading Lucentis Biosimilar in the United States

author_avatar
NASDAQ Market News